Six weeks into the turmoil spurred by U.S. President Donald Trump's "Liberation Day" tariffs, the recurring lessons seem to be: wait for the details and buy the dip.
The China and U.S. rapprochement, resulting in a suspension of the worst tariffs between the world's two biggest economies for 90 days, was better than expected, and reverberated in Asian equity markets with strong gains in Japan after a rally in the United States.
And while a Trump social media post on Sunday about high U.S. drug prices caused a massive selloff in Japanese pharma shares on Monday, the actual executive order puts the bullseye more on cheaper drugs overseas, prompting a bounce back in healthcare stocks on the Nikkei.
Keep an eye on the European pharma stock index, which has outperformed the broader index so far this year.
Trump's comments about a pricey "fat shot drug", presumably speaking of injectable obesity treatments from Novo Nordisk and Eli Lilly, could mean pressure for cost cuts in the U.S. or increases in Europe.
Or both. Comments from Bayer AG after first-quarter results today may give a read on how the German healthcare giant plans to navigate the uncertain road ahead.
No comments:
Post a Comment